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 Radioactive iodine therapy (RAI) has been used in patients with differentiated thyroid cancers (DTC) for many decades.  
However, many changes in thyroid cancer treatment have been introduced for the last decade worldwide, mainly a tendency 
to deescalate both surgical and adjuvant treatment has been observed. This work summarizes current Polish guidelines 
for adjuvant radioiodine therapy compared to American Thyroid Association recommendations.
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Radioactive iodine (RAI) has been used for the postsurgical tre-
atment of differentiated thyroid cancer (DTC) for over 50 years. 
Its therapeutic application in DTC is related to the ability of 
thyroid cells (both normal and cancerous) to actively capture 
iodine, including RAI, which is a β radiation emitter [1]. The in-
corporation of RAI into a thyrocyte cell leads to the formation of 
free radicals that damage the DNA structure and contribute to 
cell death or loss of its growth and division potential. For many 
years, radioiodine treatment was routinely recommended as 
an adjunct to surgery regardless of the disease recurrence or 
death risk.
The last decade has introduced many changes related to 
DTC treatment. With the development of new diagnostic me-
thods, such as thyroglobulin (Tg) measurement or ultrasound 
examination, as well as better understanding of the biology 
and natural history of DTC, routine post-surgical radioiodine 
treatment has been questioned. A tendency to deescalate 
both surgical and adjuvant treatment has been observed [2]. 
However, the targets of adjuvant 131I have remained unchan-
ged and include the following:
• ablation of residual normal thyroid tissue, which may fa-
cilitate surveillance, 
• ‘adjuvant therapy’ due to a potential tumoricidal effect on 
residual microscopic RAI-avid disease, 
• the possibility of detection of unknown local or distant 
metastases in a post-treatment whole-body scan.
While all the above targets are important, the ultimate 
endpoint of postsurgical ablation is to minimise DTC recurren-
ce and death, primarily by eliminating residual normal thyroid 
tissue or residual microscopic disease.
In patients with structural disease, particularly in patients 
with non-resectable disease or after a non-radical operation 
(R2) or with distant metastases, radioiodine therapy is not 
adjuvant treatment. In these cases, the target of radioiodine 
therapy is complete disease remission or palliative intension. 
There are no indications for radioiodine treatment in patients 
with anaplastic or medullary thyroid cancer.
Of note, treatment recommendations for DTC radioiodine 
therapy have changed over time and vary among countries. Whi-
le American Thyroid Association (ATA) guidelines have become 
more and more restricted regarding the use of radioiodine, other 
countries, including Poland, are more open to recommending 
radioiodine therapy [3–5]. The main reason for this discrepancy 
is the lack of prospective randomised trials in DTC radioiodine 
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other advancement stages, eligibility for the extent of surgery 
and adjuvant radioiodine therapy is open to debate. 
According to the ATA 3-stage recurrence risk classification, 
patients with lymph node micrometastases (<2 mm in diame-
ter) whose number does not exceed 5 are included in the low 
risk group and radioiodine therapy is not routinely recommen-
ded. However, Polish guidelines recommend adjuvant RAI tre-
atment in all patients with lymph node metastases irrespective 
of their diameter, number or location (pN1a, pN1b) (Tab. II, III). 
According to the ATA, patients staged pT1b-T2N0 are inclu-
ded in the low risk group and in this case the ATA recommends 
lobectomy without adjuvant 131I treatment. 
Currently in Poland, lobectomy is only performed in pa-
tients staged cT1aN0M0, as opposed to ATA recommendations 
[4]. In Poland, as in other European countries, patients staged 
pT1b-T2N0M0 receive adjuvant radioiodine treatment consi-
derably more often.
Obviously, one of the reasons for such management is the 
different extent of surgical treatment (total or near-total thy-
roidectomy), the different courses of the disease, depending 
on the region of the world and the very good results of such 
management reported in European countries.
According to the Polish recommendations, adjuvant 
radioiodine therapy may be abandoned in patients staged 
pT1b-T2N0M0 if negative prognostic factors (e.g., aggressive 
histological subtype or angioinvasion) were not found posto-
peratively and the potential benefits of such management 
outweigh the risk of recurrence [4].
Similarly, differences are also noted in terms of recommen-
dations for adjuvant therapy in patients from the intermediate 
risk group (Tab. III). In Poland, these patients are routinely quali-
fied for 131I treatment, while in the United States abandonment 
of RAI treatment is permissible. 
treatment. Outside the radioiodine-refractory DTC setting, only 
two prospective randomised trials have been published [6, 7]. 
They are, however, related to the preparation for RAI therapy 
or RAI activity rather than to the indications for such therapy.
Eligibility for adjuvant 131I treatment in DTC is mainly based 
on a 3-stage recurrence risk classification (Tab. I) developed by 
the ATA [2]. The TNM classification alone is no longer sufficient 
and hence a detailed histological assessment is necessary. It 
should include information related to the size of the primary 
lesion, multifocality, histological subtypes of the cancer, the 
presence and the extent of the extrathyroid infiltration, angio-
invasion and the assessment of the number and the diameter 
of lymph node (micro/macro) metastases. In the future, the 
diagnosis of the molecular status of the tumour (i.e. the pre-
sence of the mutation of increased risk of unfavourable disease 
course such as BRAF or TERT) may be necessary. However, 
currently it is not routinely considered at the time of patient 
eligibility for adjuvant treatment. Other significant factors for 
such therapy also include the measurement of postoperative 
Tg concentration.
Although the ATA recurrence risk scale (Tab. I) was accepted 
in Europe and Poland, its interpretation is different compared to 
the USA, particularly in patients from the intermediate recurren-
ce risk group [5]. Both Polish and American guidelines stress the 
necessity of adjuvant radioiodine treatment in patients from the 
high risk group in whom histological findings revealed extrathy-
roid infiltration (pT4), the diameters of metastases ≥3 cm and 
angioinvasion of more than 4 vessels in follicular thyroid carci-
noma or if high postoperative concentration of Tg is found [2, 4].
Adjuvant radioiodine therapy can be abandoned in pa-
tients from the low risk group in case of papillary thyroid cancer 
(pT1a) without other negative risk factors, which is consistent 
with European and American guidelines (Tab. II). However, in 
Table I. 3-stage recurrence risk classification of differentiated thyroid cancers based on the 2015 American Thyroid Association Guidelines [2]
Low risk group Intermediate risk group High risk group
Papillary thyroid cancer with all of the following: 
– no local or distant metastases; 
– total macroscopic tumour resection; 
– no extrathyroid extension;  
– no aggressive histology of tumour (e.g., 
tall cell, hobnail variant, columnar cell 
carcinoma); 
– no vascular invasion; 
– clinical N0 or <5 pathologic N1 
micrometastases (<0.2 in largest dimension); 
– if 131I is given, there are no RAI-avid foci 
outside the thyroid bed on the first 
posttreatment whole-body scan.  
Intrathyroidal, well differentiated follicular 
thyroid cancer without  capsular or vascular 
invasion or minimal (<4 foci) vascular invasion. 
Intrathyroidal, papillary microcarcinoma, unifocal 
or multifocal, including BRAFV600E
mutation. 
– microscopic invasion of tumour into the 
perithyroidal soft tissues;
– aggressive histology; 
– papillary thyroid cancer with vascular 
invasion;
– clinical N1 or >5 pathologic N1 with 
all involved lymph nodes (0.2–3 cm in 
dimension);
– multifocal papillary microcarcinoma with 
extrathyroid extension and the presence of 
BRAFV600E mutation; 
– if 131I is given, there are RAI-avid foci outside 
the thyroid bed on the first posttreatment 
whole-body scan.  
– gross extrathyroid extension; 
– incomplete tumour resection; 
– distant metastases; 
– postoperative serum thyroglobulin level 
suggestive of distant metastases; 
– pathological N1 with any metastatic lymph 
node ≥3 cm in largest dimension; 
– follicular thyroid cancer with extensive 
vascular invasion (>4 foci).
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Eligibility for 131I adjuvant treatment is related to time after 
surgery and thyroid remnant volume. Radioiodine treatment 
should be performed at the earliest about 4 weeks postopera-
tively when the wound has healed, the postoperative oedema 
has resolved, and the Tg level has decreased. According to 
the Polish recommendations, therapy should be performed 
within 9 months after surgery, and when this period exceeds 
9–12 months, the treatment is considered delayed. Indications 
for adjuvant radioiodine treatment 12 months after surgical 
procedure is questionable [4]. 
Large thyroid remnants (>1 ml on either site of the thyroid 
bed) are relative contraindications for radioiodine adjuvant 
treatment, since with large thyroid remnants treatment success 
rate is worse. Higher or repeated RAI activities are necessary, 
which results in increased RAI therapy-related risks [4].
A high level of thyroid stimulating hormone (TSH) is es-
sential for RAI uptake by thyroid cells. Traditionally, a high level 
of TSH has been achieved by withholding thyroxine therapy 
for 4–6 weeks after surgery. As a result, hypothyroidism can 
affect the quality of life of patients and lead to the imbalance 
of several biochemical parameters, particularly in the elderly. 
Recombinant human TSH (rhTSH) was developed to facilitate 
RAI application without withholding thyroxine. In most Polish 
radioiodine treatment centres, rhTSH is the preferred method 
of TSH stimulation. Therefore, there is no need to delay L-thy-
roxine therapy in patients after thyroid surgery. 
To conclude, in Poland postoperative radioiodine 
therapy is given to patients: 
a) from the high and intermediate risk groups 
b) from the low risk group if:
– lymph node micrometastases are found in the posto-
perative histological examination,
– an increased concentration of Tg is found postopera-
tively (stimulated Tg level >10 ng/dl), 
– iodine accumulation is observed outside the thyroid bed.
Conflicts of interest: none declared
Agnieszka Czarniecka
M. Sklodowska-Curie National Research Institute of Oncology,  
Gliwice Branch 
The Oncological and Reconstructive Surgery Clinic 
ul. Wybrzeże Armii Krajowej 15 
44-102 Gliwice, Poland
e-mail: agnieszka.czarniecka@io.gliwice.pl
Received and accepted: 26 Feb 2020
Acknowledgments
We acknowledge the linguistic assistance provided by Assi-
stant Professor Arkadiusz Badziński, Ph.D., a medical translator, 
in the preparation of this manuscript. 
Table II. Comparison of recommendations for adjuvant radioiodine treatment in patients from the low risk group based on Polish and American recommendations 
[2, 3]
Advancement Strength of 
recommendation  
ATA 2015 guidelines  Polish 2018 guidelines  
T1a   
N0 (x) 
M0 (x)
lesion ≤1 cm
unifocal 
multifocal 
strong
weak
no
no
no
no
T1b, T2 
N0 (x) 
M0 (x)
micro N1
M0 (x)
lesion(s) of 1–4 cm with no 
lymph node metastases or with 
the presence of lymph node 
micrometastases, with no distant 
metastases and with no other 
negative prognostic factors found 
in histological examination
weak selectively therapy can be abandoned after 
the assessment of postsurgical 
treatment 
(not applicable to patients with 
N1)
Table III. Comparison of recommendations for adjuvant radioiodine treatment in patients from  the intermediate risk group based on Polish and American 
recommendations [2, 3]
Advancement Strength of 
recommendation  
ATA 2015 guidelines  Polish 2018 guidelines  
T3  
N0 (x)
lesion >4 cm weak consider yes
T3
N0 (x)
extrathyroid extension weak consider/rather yes yes
T1–3 
N1a
central lymph node metastases weak consider/rather yes yes
T1–3
N1b
lateral lymph node metastases weak consider/rather yes yes
68
References
1. Choudhury PS, Gupta M. Differentiated thyroid cancer theranostics: 
radioiodine and beyond. Br J Radiol. 2018; 91(1091): 20180136, doi: 
10.1259/bjr.20180136, indexed in Pubmed: 30260232.
2. Haugen BR, Haugen BR, Alexander EK, et al. 2015 American Thyroid 
Association Management Guidelines for Adult Patients with Thyroid 
Nodules and Differentiated Thyroid Cancer: The American Thyroid As-
sociation Guidelines Task Force on Thyroid Nodules and Differentiated 
Thyroid Cancer. Thyroid. 2016; 26(1): 1–133, doi: 10.1089/thy.2015.0020, 
indexed in Pubmed: 26462967.
3. Treglia G, Aktolun C, Chiti A, et al. EANM and the EANM Thyroid Com-
mittee. The 2015 Revised American Thyroid Association guidelines for 
the management of medullary thyroid carcinoma: the „evidence-based” 
refusal to endorse them by EANM due to the „not evidence-based” 
marginalization of the role of Nuclear Medicine. Eur J Nucl Med Mol 
Imaging. 2016; 43(8): 1486–1490, doi: 10.1007/s00259-016-3404-7, 
indexed in Pubmed: 27118126.
4. Jarząb B, Dedecjus M, Słowińska-Klencka D, et al. Guidelines of Polish 
National Societies Diagnostics and Treatment of Thyroid Carcinoma. 
2018 Update. Endokrynol Pol. 2018; 69(1): 34–74, doi: 10.5603/
EP.2018.0014, indexed in Pubmed: 29442352.
5. Luster M, Aktolun C, Amendoeira I, et al. European Perspective on 
2015 American Thyroid Association Management Guidelines for 
Adult Patients with Thyroid Nodules and Differentiated Thyroid 
Cancer: Proceedings of an Interactive International Symposium. 
Thyroid. 2019; 29(1): 7–26, doi: 10.1089/thy.2017.0129, indexed in 
Pubmed: 30484394.
6. Schlumberger M, Leboulleux S, Catargi B, et al. Outcome after ablation 
in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-
-up results of a randomised, phase 3, equivalence trial. The Lancet 
Diabetes & Endocrinology. 2018; 6(8): 618–626, doi: 10.1016/s2213-
-8587(18)30113-x.
7. Dehbi HM, Mallick U, Wadsley J, et al. Recurrence after low-dose radio-
iodine ablation and recombinant human thyroid-stimulating hormone 
for differentiated thyroid cancer (HiLo): long-term results of an open-
-label, non-inferiority randomised controlled trial. Lancet Diabetes 
Endocrinol. 2019; 7(1): 44–51, doi: 10.1016/S2213-8587(18)30306-1, 
indexed in Pubmed: 30501974.
